Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Understanding the presence and function of erythropoietin receptors on cancer cells.

Lai SY, Grandis JR.

J Clin Oncol. 2006 Oct 10;24(29):4675-6. No abstract available.

PMID:
17028292
2.

Preclinical studies of erythropoietin receptor expression in tumour cells: impact on clinical use of erythropoietic proteins to correct cancer-related anaemia.

Osterborg A, Aapro M, Cornes P, Haselbeck A, Hayward CR, Jelkmann W.

Eur J Cancer. 2007 Feb;43(3):510-9. Epub 2006 Dec 5. Review.

PMID:
17150352
3.

Consensus on the Existence of Functional Erythropoietin Receptors on Cancer Cells.

Bennett CL, Lai SY, Sartor O, Georgantopoulos P, Hrushesky WJ, Henke M, Armitage JO.

JAMA Oncol. 2016 Jan;2(1):134-6. doi: 10.1001/jamaoncol.2015.3940. Review. No abstract available.

PMID:
26606114
4.

Erythropoietin receptors on tumor cells: what do they mean?

Fandrey J.

Oncologist. 2008;13 Suppl 3:16-20. doi: 10.1634/theoncologist.13-S3-16. Review.

5.

Erythropoietin in cancer: presumption of innocence?

Blau CA.

Stem Cells. 2007 Aug;25(8):2094-7. Epub 2007 Apr 26. Review.

6.

The cellular biology of erythropoietin receptors.

Lappin T.

Oncologist. 2003;8 Suppl 1:15-8. Review.

7.

Erythropoietin therapy and cancer related anaemia: updated Swedish recommendations.

Ahlqvist-Rastad J, Albertsson M, Bergh J, Birgegård G, Johansson P, Jonsson B, Kjellen E, Påhlman S, Zackrisson B, Osterborg A.

Med Oncol. 2007;24(3):267-72. Review.

PMID:
17873301
8.

Erythropoietin: physiology and molecular mechanisms.

Foley RN.

Heart Fail Rev. 2008 Dec;13(4):405-14. doi: 10.1007/s10741-008-9083-0. Epub 2008 Jan 31. Review.

PMID:
18236154
9.

Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.

Nowrousian MR, Dunst J, Vaupel P.

Strahlenther Onkol. 2008 Mar;184(3):121-36. doi: 10.1007/s00066-008-1841-3. Review.

PMID:
18330508
10.

Therapeutic strategy of erythropoietin in neurological disorders.

Liu XB, Wang JA, Yu SP, Keogh CL, Wei L.

CNS Neurol Disord Drug Targets. 2008 Jun;7(3):227-34. Review.

PMID:
18673207
11.

Erythropoietin in cancer patients.

Glaspy JA.

Annu Rev Med. 2009;60:181-92. doi: 10.1146/annurev.med.60.050307.110718. Review.

PMID:
18980468
12.

Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives.

Arcasoy MO.

Clin Cancer Res. 2008 Aug 1;14(15):4685-90. doi: 10.1158/1078-0432.CCR-08-0264. Review.

13.

Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients.

Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG.

Cancer. 2007 Aug 1;110(3):477-88. Review.

14.

Erythropoietin and the endothelium - a promising link?

Fliser D, Bahlmann FH.

Eur J Clin Invest. 2008 Jul;38(7):457-61. doi: 10.1111/j.1365-2362.2008.01968.x. Epub 2008 May 21. Review.

PMID:
18505404
15.

New agents that stimulate erythropoiesis.

Bunn HF.

Blood. 2007 Feb 1;109(3):868-73. Epub 2006 Oct 10. Review.

16.

Protective effects of erythropoietin in cardiac ischemia: from bench to bedside.

Lipsic E, Schoemaker RG, van der Meer P, Voors AA, van Veldhuisen DJ, van Gilst WH.

J Am Coll Cardiol. 2006 Dec 5;48(11):2161-7. Epub 2006 Nov 9. Review.

17.

Erythropoietin in cancer-related anemia.

Fenner MH, Ganser A.

Curr Opin Oncol. 2008 Nov;20(6):685-9. doi: 10.1097/CCO.0b013e3283136971. Review.

PMID:
18841051
19.

[Erythropoietin - state of science].

Schöffel N, Börger JA, Quarcoo D, Scutaru C, Groneberg DA.

Sportverletz Sportschaden. 2008 Dec;22(4):201-6. doi: 10.1055/s-2008-1027826. Epub 2008 Dec 15. Review. German.

PMID:
19085770
20.

Erythropoietin in cancer: the new face of an old friend.

Megalakaki C.

J BUON. 2008 Jan-Mar;13(1):7-16. Review.

PMID:
18404780

Supplemental Content

Support Center